Your browser doesn't support javascript.
loading
SIX4 upregulates IDH1 and metabolic reprogramming to promote osteosarcoma progression.
Li, Bing; Dang, Xiaoqian; Duan, Jiafeng; Zhang, Guangyang; Zhang, Jia; Song, Qichun.
Afiliación
  • Li B; Department of Orthopaedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Dang X; Department of Orthopaedics, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, China.
  • Duan J; Department of Orthopaedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Zhang G; Department of Implant, Nobel Stomatology Hospital, Xi'an, China.
  • Zhang J; Department of Orthopaedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Song Q; Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, China.
J Cell Mol Med ; 27(2): 259-265, 2023 01.
Article en En | MEDLINE | ID: mdl-36601689
ABSTRACT
Metabolism reprogramming plays an important role in tumorigenesis and osteosarcoma metastasis. Sine oculis homeobox 4 (SIX4) is reported to be a key transcription factor that is involved in glycolysis reprogramming of cancer cells. However, the role of SIX4 in osteosarcoma progression remains unknown. The expression profile of SIX4 in OS was evaluated in surgery samples of osteosarcoma patients. Functional studies were performed in vitro and in vivo. We found that SIX4 is significantly overexpressed in osteosarcoma and related to the undesirable prognosis of osteosarcoma patients. SIX4 promotes progression of osteosarcoma via upregulating isocitrate dehydrogenase 1 (IDH1), which provides novel prognostic biomarkers and promising therapeutic targets for osteosarcoma patients.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteosarcoma / Transactivadores Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Cell Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteosarcoma / Transactivadores Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Cell Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2023 Tipo del documento: Article País de afiliación: China
...